Fluifort, 5 g 10 pcs

Fluifort has mucoregulatory, expectorant action.

Pharmacodynamics

The mucolytic and expectorant action is due to the activation of sialic transferase – an enzyme of the mucous membrane of the bronchi. It normalizes the quantitative ratio of acidic and neutral sialomucin of bronchial secretion, restores viscosity and elasticity of mucus.

Promotes regeneration of the mucous membrane, normalizes its structure, activates the ciliated epithelium. Restores the secretion of immunologically active IgA (specific protection) and the number of sulfhydryl groups of mucus components (nonspecific protection), improves mucociliary clearance.

Pharmacokinetics

It is rapidly and completely absorbed after oral administration. C_max in blood and secretion is reached within the first hour after drug administration. Therapeutic concentration is retained in the blood for 8 hours. T_1/2 is 1.8 hours (at a dose of 2 g/day).

Extracted mainly in the urine, about 30-60% is unchanged, the rest as metabolites.

Indications

Acute and chronic bronchopulmonary diseases accompanied with formation of viscous and hardly discharged sputum (tracheitis, bronchitis, tracheobronchitis, bronchial asthma, bronchiectatic disease) and mucus (inflammatory diseases of the middle ear and accessory sinuses – rhinitis, adenoiditis, otitis media, sinusitis).

Patient preparation for bronchoscopy or bronchography.

Active ingredient

Composition

1 sachet of granules for the preparation of suspension for oral administration contains:

the active ingredient:

carbocysteine lysine salt monohydrate 2.7 g,

excipients:

citric acid, 0.080 g;

mannitol, 0.9185 g;

PVP – 0.1 g;

Cedarwood natural flavoring – 0.04 g;

p> orange flavoring natural – 0,04 g;

orange juice powder – 0,2960 g;

aspartame – 0.03 g;

maltodextrin – 0.7955 g

How to take, the dosage

Adults: 1 sachet a day. Dissolve the contents of the sachet in drinking water, mix.

The duration of treatment is determined by the doctor (from 4 days to 6 months).

The indicated dosage is maintained for patients with impaired liver and kidney function, as well as for patients with diabetes.

Interaction

There are currently no known interactions between carbocysteine and drugs commonly used in the treatment of respiratory diseases.

There are no identified interactions of the drug and food, as well as substances used for laboratory studies.

The effect is weakened by anti-cough and m-cholinoblocking drugs.

Induces the effectiveness of GCS (reciprocally) and antibacterial therapy of infectious and inflammatory diseases of the upper and lower respiratory tract.

It enhances the bronchodilator effect of theophylline.

Special Instructions

From the first days of taking the drug due to improved secretion elimination the expectorant effect increases.

Fluifort in the form of granules for suspension contains the sweetener aspartame. This substance is contraindicated in patients with phenylketonuria.

Contraindications

With caution: pregnancy (II-III trimester); peptic ulcer and duodenal ulcer (in anamnesis).

Side effects

The following side effects are characteristic of carbocysteine: rarely – gastritis, nausea, diarrhea, dizziness, malaise, skin rash.

Lysine salt of carbocysteine: rarely – epigastric pain, nausea, diarrhea; skin rash.

All of the above disorders are transient and disappear after discontinuation of the drug or after reducing the dosage.

Contact your doctor if any of the side effects develop.

Overdose

To date, no cases of overdose with the drug Fluifort have been reported.

Symptoms: pain in the stomach, nausea, diarrhea are possible.

Treatment: symptomatic. There is no specific antidote.

Pregnancy use

It is not recommended in the first trimester of pregnancy, breastfeeding should be stopped during treatment.

Similarities